Statement from FDA on continuing efforts to maintain its strong oversight of generic drugs
date:Feb 25, 2019
spection strategy to focus inspectional resources on higher risk facilities and works closely with our international regulatory partners in Europe to avoid duplication of inspections. For instance, while surveillance inspections declined slightly in China from 2017-18, inspections in India have increased substantially. Among other things, the number of inspections in any given country reflects our risk-based prioritization of our inspections and improvements in our targeting; our increasing abil
21/35 next page prev page home page last page
go back |  refresh |  WAP home |  Web page version  | login
06/19 16:15